"Survival Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
| Descriptor ID |
D016019
|
| MeSH Number(s) |
E05.318.740.998 N05.715.360.750.795 N06.850.520.830.998
|
| Concept/Terms |
Survival Analysis- Survival Analysis
- Analysis, Survival
- Analyses, Survival
- Survival Analyses
|
Below are MeSH descriptors whose meaning is more general than "Survival Analysis".
Below are MeSH descriptors whose meaning is more specific than "Survival Analysis".
This graph shows the total number of publications written about "Survival Analysis" by people in this website by year, and whether "Survival Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1994 | 0 | 3 | 3 |
| 1996 | 0 | 3 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 7 | 7 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 5 | 5 |
| 2005 | 1 | 6 | 7 |
| 2006 | 0 | 7 | 7 |
| 2007 | 0 | 14 | 14 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 17 | 17 |
| 2011 | 0 | 12 | 12 |
| 2012 | 0 | 11 | 11 |
| 2013 | 0 | 6 | 6 |
| 2014 | 0 | 12 | 12 |
| 2015 | 1 | 20 | 21 |
| 2016 | 0 | 11 | 11 |
| 2017 | 0 | 14 | 14 |
| 2018 | 0 | 5 | 5 |
| 2019 | 0 | 13 | 13 |
| 2020 | 0 | 11 | 11 |
| 2021 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Survival Analysis" by people in Profiles.
-
Survival analyses of soft tissue pleomorphic sarcomas and a proposed leiomyosarcoma-specific dynamic nomogram: A large population-based study. Pathol Res Pract. 2022 Sep; 237:153999.
-
Long-term outcomes of primary cardiac malignant tumors: Difference between African American and Caucasian population. Cancer Med. 2021 12; 10(24):8838-8845.
-
The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Mol Cancer Ther. 2021 11; 20(11):2166-2176.
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.
-
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021 05; 161(2):382-388.
-
An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer. EBioMedicine. 2021 Mar; 65:103271.
-
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol. 2020 12 01; 6(12):1952-1956.
-
Cooperation between ETS transcription factor ETV1 and histone demethylase JMJD1A in colorectal cancer. Int J Oncol. 2020 12; 57(6):1319-1332.
-
The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer. 2020 Sep 21; 20(1):897.
-
Fibrinogen-Coated Albumin Nanospheres Prevent Thrombocytopenia-Related Bleeding. Radiat Res. 2020 08 01; 194(2):162-172.